KPV: the three-amino-acid tail of a tanning hormone, studied for inflammation

A hormone's last three letters

Alpha-MSH is best known as the hormone that tells skin cells to make pigment. It is a 13-amino-acid peptide cut from a larger precursor protein, and it also turns out to be a powerful brake on inflammation ^[2]. The trouble with using it as an anti-inflammatory is the tan that comes with it ^[2].

So researchers asked an obvious question: how much of the molecule is actually needed? For the anti-inflammatory part, the answer appeared to be very little. The final three residues, Lys-Pro-Val, kept much of the effect and lost the pigmenting one ^[2]. That fragment is KPV.

The appeal is easy to see. A three-residue peptide is cheap to make and small enough to slip into cells through transporters normally used for digested protein ^[2,3]. The question this article tries to answer is how far the evidence has travelled from that appealing idea.

Origin: a fever lab in Dallas

KPV's story begins in research on fever. Alpha-MSH lowers fever in animals, and that effect was believed to reside in its C-terminal tripeptide ^[1]. In 1989, M. E. Hiltz and J. M. Lipton in Dallas tested whether the same tripeptide could reduce inflammation more generally ^[1].

They used the chemical picryl chloride to provoke ear swelling in mice, then compared KPV with saline and with a large dose of corticosteroid. KPV reduced ear swelling in a dose-related way ^[1]. The authors suggested that drugs based on the tripeptide might one day treat inflammation ^[1].

Over the following decades the work moved to Münster in Germany, where researchers studied KPV and a related tripeptide, KdPT, for skin and bowel inflammation ^[2,4], and to Atlanta, where a gastroenterology group showed how KPV gets into gut cells ^[3].

How it works: blocking a messenger at the door

Inflammation in many cell types is switched on by NF-κB, a protein complex that sits in the cell's cytoplasm until a danger signal arrives. It then moves into the nucleus and turns on genes for inflammatory messengers ^[3,7].

KPV appears to interfere with that journey. In human intestinal and immune cells, nanomolar KPV blocked NF-κB and related MAP kinase signalling and reduced the release of inflammatory cytokines ^[3]. It got into the cells through PepT1, a transporter that normally absorbs small peptides from digested food. PepT1 is found mainly in the small intestine, but it is switched on in the colon during inflammatory bowel disease ^[3].

Think of NF-κB as a messenger carrying an alarm into the control room. In airway cells, KPV itself entered the nucleus and appeared to block the doorway the NF-κB subunit p65 normally uses to get in ^[7].

That picture is not complete. Some effects of KPV persisted in mice lacking a working melanocortin-1 receptor, the main receptor for alpha-MSH, which points to a receptor-independent route ^[4]. Yet in skin cells and in cells engineered to carry that receptor, KPV triggered calcium signals, suggesting some receptor involvement too ^[8]. FDA's 2026 review concluded that the molecular targets of KPV remain unknown ^[10].

What the research shows

Gut inflammation in mice

• Dalmasso and colleagues, 2008: KPV in drinking water reduced chemically induced colitis in two mouse models (DSS and TNBS), with lower inflammatory cytokine levels in the colon ^[3].
• Kannengiesser and colleagues, 2008: In DSS colitis and in a T-cell transfer model, KPV-treated mice regained weight faster and had less inflammation in colon tissue. In mice without a functional melanocortin-1 receptor, KPV prevented deaths from DSS colitis ^[4].

Getting KPV to the colon

A drug for colitis has to reach the colon intact. The Atlanta group packed KPV into nanoparticles about 400 nanometres across, wrapped in a gel that breaks down in the colon ^[5]. In mice with DSS colitis, the particles worked at a KPV concentration about 12,000 times lower than free KPV in solution ^[5].

Packed into colon-targeted nanoparticles, KPV matched the effect of free KPV at a concentration 12,000-fold lower, in mice ^[5].

A 2017 version coated the particles with hyaluronic acid so that they would be taken up by colon lining cells and immune cells. This gave stronger protection against colitis in mice than uncoated particles ^[6].

Skin

• The original 1989 study was itself a skin model: chemically induced ear swelling in mice ^[1].
• In human keratinocytes, the main cells of the outer skin, KPV triggered calcium signalling ^[8].
• A 2025 cell study found that KPV protected keratinocytes from fine-dust pollution, reducing cell death and the inflammatory messenger IL-1β, including in a three-dimensional skin model ^[9].

One practical limit: an in vitro test found that KPV did not pass through human cadaver skin ^[10].

Airways

In human bronchial cells exposed to TNF-α or respiratory syncytial virus, KPV reduced NF-κB activity and the release of the chemokines IL-8 and eotaxin ^[7].

In humans

There are no published human studies. FDA's 2026 review found no clinical studies or human exposure data for KPV by any route ^[10]. Of the nine references submitted to FDA in support of KPV, none involved people ^[10].

What we don't know yet

Whether it works in people. Every efficacy result so far comes from cells or mice ^[10]. Mouse colitis models are useful screens but often fail to predict human results.

How it gets where it needs to go. Oral KPV relies on PepT1 in the gut ^[3], and topical KPV may not cross intact skin ^[10]. Nothing is known about its fate in the human body.

What it binds to. The evidence points to both receptor-dependent and receptor-independent actions, and FDA considers the targets unknown ^[4,8,10].

Safety. FDA found no acute, repeat-dose, genetic, reproductive or cancer toxicology studies, and no information on immune reactions ^[10]. A tiny peptide is not automatically a safe one.

Regulatory status

• Approval: KPV is not approved as a medicine anywhere, and no human study has been published ^[10].
• FDA, 2023: Placed in Category 2 on 29 September 2023 because FDA found no human exposure data and lacked important safety information ^[11].
• FDA, 2026: After the nomination was withdrawn, KPV was moved to the "nominated but withdrawn" list by April 2026 ^[11]. FDA staff still reviewed it for wound healing and inflammatory conditions, the uses proposed for a 0.1% cream or gel, and recommended against listing ^[10]. On 23 July 2026 the advisory committee voted 8 to 6, with one abstention, in favour ^[12,14]. The vote is advisory; listing would require FDA rulemaking ^[14].
• Sport: KPV is not named on the WADA Prohibited List, but anti-doping agencies treat non-approved peptides as falling under class S0 ^[13].

In the lab: handling and storage

KPV is supplied as a lyophilised powder, either as the free peptide or as an acetate salt; FDA treats these as two different substances ^[10]. The free peptide is reported to be stable for up to three years at −20 °C ^[10], in line with general practice for research peptides: −20 °C long term, 2-8 °C short term, protected from light and moisture. FDA also notes limited water solubility for the free peptide, about 0.7 mg/mL ^[10], which is worth knowing when planning stock solutions. Reconstituted solutions are generally refrigerated and used promptly.

FAQ